The company’s most advanced compounds, PK100 series targeted against PKCδ, a novel PKC isoform are currently being tested in animal models of Parkinson’s disease and in preclinical stage.Indications are that it slows or halts disease progression in animal PD models.

The company’s PK200 series of compounds targeted against neuronal apoptotic cell signaling molecules are in lead optimization stage and in some of them are currently being tested in cell culture and animal models of neuroinflammation and neurodegeneration.

The company’s PK300 series of compounds targeted against microglial activators are in lead optimization stage and in some of them are currently being tested in cell culture and animal models of neuroinflammation and neurodegeneration.

PK Biosciences does not claim that this technology or any of its product candidates are safe or will be effective in preventing, treating or curing any disease or condition.